Core Viewpoint - The research published by Francis Crick Institute in Nature highlights the role of antibodies against endogenous retroviruses (ERVs) in enhancing lung cancer immunotherapy, suggesting a potential therapeutic strategy combining CXCL13 with immune checkpoint blockade (ICB) therapy [4][5]. Group 1 - The study reveals that tertiary lymphoid structures (TLS) improve the efficacy of lung cancer immunotherapy by enabling B cells to produce antibodies targeting activated ERVs within tumor cells [4][5]. - Immune checkpoint blockade (ICB) therapy enhances the B cell response against ERVs, and the resulting antibodies exhibit anti-tumor effects and can predict treatment efficacy [4][5]. - The formation of TLS is dependent on the cytokine CXCL13, and utilizing CXCL13 in treatment could synergize with existing ICB therapies for better anti-cancer outcomes [4][5]. Group 2 - The paper was retracted on January 14, 2026, due to issues found in the data presented in the figures, which were critical to the study's conclusions [6][8]. - Specific problems included irreproducible data in figure 5c, potential data manipulation in figures 5d and 5e, and unverifiable source data integrity for B cell and antibody quantification in figures 3c and extended data figure 5c [8][9]. - The investigation indicated that the first author, Kevin W. Ng, was responsible for the data manipulation issues, and the authors issued an apology to the scientific community for any confusion caused [12].

Core Viewpoint - The article discusses a novel approach to cancer immunotherapy through the development of an intratumoral vaccination chimera (iVAC) that combines immune checkpoint degradation with high-quality antigen presentation, aiming to enhance anti-tumor immunity and overcome immune evasion by tumors [4][5][7]. Group 1: Mechanisms of Tumor Immune Evasion - Tumors evade immune surveillance through various mechanisms, including the overexpression of inhibitory checkpoint proteins and impaired antigen presentation [3]. - The lack or dysfunction of tumor-specific cytotoxic T lymphocytes (CTLs) limits the response rates to immune checkpoint blockade (ICB) therapies [3]. Group 2: Development of iVAC - The research team developed the iVAC, which covalently links PD-L1 degradation agents with immunogenic antigens, enabling the reprogramming of tumor cells into antigen-presenting cell-like states [5][7]. - iVAC induces strong tumor-killing effects by reactivating resident antigen-specific CD8+ T cells and reshaping the tumor microenvironment to promote durable tumor-specific immunity [5][7]. Group 3: Experimental Validation - The iVAC technology was validated using antigens derived from cytomegalovirus (CMV) to activate CMV-specific T cells targeting breast cancer in vitro, in humanized mouse models, and in patient-derived tumor models [7]. - This innovative strategy transforms tumor cells into allies of the immune system, paving the way for more effective cancer immunotherapies [7].

Core Viewpoint - The research highlights the role of uridine as an immune metabolite that regulates CD8⁺ T cell activity, revealing a molecular mechanism by which cancer cells suppress anti-tumor immunity by depleting uridine levels in the tumor microenvironment [8]. Group 1: Research Findings - The study published in Cell Metabolism identifies a new mechanism by which uridine mediates N-glycosylation of CD45 protein, promoting CD8⁺ T cell anti-tumor immunity [3]. - It details the process and regulatory mechanisms of uridine depletion in the tumor microenvironment, proposing new therapeutic targets and combination treatment strategies for immune therapy resistance [3]. - The research indicates that SNX17 expression negatively correlates with CD8⁺ T cell infiltration and sensitivity to immune checkpoint blockade (ICB) therapy [5]. Group 2: Mechanisms and Implications - SNX17 regulates the metabolic microenvironment, inhibiting CD8⁺ T cell function, and its knockout leads to significantly increased uridine levels in tumor cell supernatants and tissues, which can activate CD8⁺ T cells and inhibit tumor growth in mice [5]. - The activation mechanism of uridine on CD8⁺ T cells involves its metabolism to UDP-GlcNAc, which promotes N-glycosylation of the key membrane protein CD45, enhancing TCR signaling and effectively activating CD8⁺ T cells [5]. - The upstream mechanism shows that SNX17 stabilizes the transcription factor RUNX2, preventing its lysosomal degradation, which in turn upregulates the expression of uridine-degrading enzyme UPP1, leading to uridine depletion in the tumor microenvironment [6]. Group 3: Clinical Relevance - The findings suggest that SNX17 could serve as a predictive biomarker for resistance to cancer immunotherapy, while uridine may represent a promising candidate for immunotherapeutic drugs [8].

Core Viewpoint - CAR-T cell therapy has shown significant efficacy in treating hematological malignancies, prompting research into its application for solid tumors, particularly glioblastoma multiforme (GBM), which presents unique treatment challenges due to its aggressive nature and lack of effective therapies [2][4]. Group 1: T Cell Exhaustion and Mechanisms - T cell exhaustion is a major barrier to the efficacy of CAR-T cell therapy in solid tumors, characterized by reduced proliferation, impaired effector function, and increased expression of inhibitory receptors [2][4]. - Recent advancements in single-cell RNA sequencing (scRNA-seq) have provided insights into the molecular mechanisms of T cell exhaustion, identifying key regulatory factors such as DNMT3A, SOX4, and PRDM1 that limit T cell anti-tumor activity [2][4]. Group 2: Research Findings on NR4A3 and FOS - A study published in Science Advances found that knocking down NR4A3 enhances CAR-T cell efficacy against malignant gliomas, but this effect diminishes due to T cell exhaustion induced by chronic antigen exposure [3][5]. - Enhancing FOS expression in NR4A3-deficient CAR-T cells can reverse T cell functional exhaustion, thereby maintaining tumor clearance capabilities and improving therapeutic efficacy [3][5][6]. Group 3: Implications for CAR-T Cell Therapy - The research highlights the critical role of NR4A3 in regulating T cell cytotoxicity and memory formation during early antigen exposure, suggesting a combined genetic modification strategy of NR4A3 knockdown and FOS overexpression to protect CAR-T cells from exhaustion [6][8]. - This dual modification approach could lead to sustained tumor clearance in solid tumors, offering a promising new strategy for optimizing CAR-T cell therapy in clinical settings [5][6].

Core Viewpoint - Immunotherapy, particularly immune checkpoint blockade (ICB), has transformed cancer treatment but remains ineffective in "cold tumors" due to immune suppression in the tumor microenvironment (TME) [2][5][6] Group 1: Research Findings - A new biomimetic Ru/TiO₂ nanobiocatalyst system inspired by natural enzyme reaction systems (ERS) has been developed, capable of rapid, pH-dependent generation of reactive oxygen species (ROS) and oxygen (O₂), effectively converting cold tumors into hot tumors [3][6][7] - The Ru/TiO₂ system enhances anti-tumor immunity and suppresses tumor metastasis when used in conjunction with ICB therapy [3][7] - This research establishes a precedent for adaptive nanobiocatalysts in the TME and paves the way for the development of next-generation immunotherapies targeting drug-resistant cancers [3][6] Group 2: Mechanism of Action - The study demonstrates that Ru/TiO₂ can mediate immunogenic cell death (ICD) in melanoma cells through endoplasmic reticulum stress, while also inhibiting hypoxia-induced immune suppression [7] - The design of Ru/TiO₂ aims to reverse immune suppression and enhance immunogenicity, transforming "immune cold" tumors into "immune hot" tumors [7] Group 3: Clinical Implications - The findings suggest that the rational design of robust and efficient biocatalytic materials could extend beyond cancer treatment, opening new avenues for immune modulation in other diseases [3][6]

Core Viewpoint - Tumor immunotherapy, particularly immune checkpoint blockade (ICB) targeting the PD-1/PD-L1 pathway, shows significant promise in treating various advanced cancers, but low immune response rates hinder its efficacy and widespread application [2] Group 1: Research Findings - The study developed a self-luminous nanosystem that enhances the activation of pyroptosis in tumor cells, leading to a strong antitumor immune response when combined with anti-PD-L1 monoclonal antibodies [3][6] - Pyroptosis, a newly discovered form of immunogenic cell death (ICD), releases pro-inflammatory cytokines and damage-associated molecular patterns, triggering a robust antigen-specific immune response [5] - The self-luminous nanoparticles can emit light within the tumor without the need for an external light source, enhancing the generation of reactive oxygen species (ROS) and achieving significant tumor-killing effects [7] Group 2: Mechanism and Components - The nanosystem consists of amphiphilic porphyrin lipids, camptothecin derivatives, and a targeting moiety, which together facilitate the release of oxygen and hydrogen peroxide in the acidic tumor microenvironment [6] - The combination of chemotherapy and self-enhanced photodynamic therapy synergistically activates pyroptosis, driving immune activation that enhances the antitumor response to PD-L1 therapy [7]

Core Viewpoint - The article discusses the development of a hydrogel-fiber composite device (HFCD) aimed at enhancing the efficacy of immune checkpoint blockade (ICB) therapy for recurrent glioblastoma (GBM) by activating cytotoxic T lymphocytes (CTL) in the postoperative tumor microenvironment (pTME) [2][3][5]. Group 1: Background on Glioblastoma and ICB Therapy - Glioblastoma (GBM) is the most common and aggressive brain tumor, accounting for approximately 57% of all gliomas, with a recurrence rate exceeding 90% due to its invasive nature [5]. - The postoperative tumor microenvironment (pTME) is characterized by immune suppression, including CTL exhaustion and infiltration of immunosuppressive cells, which reduces the clinical benefits of ICB therapy [5][6]. - There is a need to reshape the immune landscape within the pTME to enhance the response and durability of ICB therapy against GBM recurrence [5][6]. Group 2: Development of HFCD - The HFCD is designed to locally activate CTLs and modulate the acidic pTME, creating a favorable niche for CTLs [3][8]. - The device releases chemokine CXCL10 and PD-L1 inhibitors in a timed manner, enhancing CTL infiltration and maintaining their cytotoxic function [3][8]. - In an in situ GBM resection model, HFCD treatment achieved a 40% rate of complete recurrence inhibition and significantly extended the median survival to 49 days [9][10]. Group 3: Mechanism of Action - HFCD consists of quaternized chitosan hydrogel and electrospun fibers, which neutralize the acidic pTME and release CXCL10 to recruit CTLs [8]. - The sustained release of PD-L1 inhibitors from the PLGA matrix maintains PD-L1 blockade, enhancing CTL recognition and cytotoxic activity against residual GBM cells [8][10]. - This strategy alleviates immune suppression in the GBM pTME and enhances the protective effect of ICB against GBM recurrence [8][10].

Core Viewpoint - The research highlights the importance of gut microbiota in enhancing the efficacy and safety of immune checkpoint blockade (ICB) therapy for cancer treatment, proposing a novel food-medicine homologous formula to improve outcomes and reduce adverse effects [2][6][10]. Group 1: Research Development - A new oral formulation, CV/APS-MS, was developed using microcapsules to co-load Chlorella vulgaris and Astragalus polysaccharides, which are recognized for their therapeutic and nutritional benefits [3][6]. - This formulation aims to prolong retention time in the gut, nourish beneficial gut microbiota, and alleviate inflammation [6][8]. Group 2: Experimental Findings - In mouse models of melanoma lung metastasis treated with ICB therapy, CV/APS-MS improved T cell-mediated anti-tumor immunity and mitigated ICB-induced colitis and pneumonia by restoring gut microbiota balance and reducing pro-inflammatory cytokines [8][10]. - The study suggests that combining food-grade bioreagents with modern medicine could be a powerful method to enhance cancer treatment efficacy and tolerance [10].

Core Viewpoint - The study highlights the role of gut microbiota, specifically the metabolite urocanic acid (UCA), in enhancing the efficacy of cancer immunotherapy when combined with tyrosine kinase inhibitors (TKIs) [3][8][11]. Group 1: Research Findings - The research demonstrates that TKIs increase the abundance of the gut bacterium Muribaculum gordoncarteri and its metabolite UCA, which enhances the response to immune checkpoint blockade (ICB) therapy [8][9]. - UCA interacts with IκBα to inhibit NF-κB activation in endothelial cells, thereby reducing the recruitment of myeloid-derived suppressor cells (MDSCs) mediated by CXCL1 [9][11]. - Higher levels of UCA and Muribaculum gordoncarteri are found in the feces of patients who respond to ICB therapy compared to non-responders, suggesting their potential as predictive biomarkers for treatment response [8][9][11]. Group 2: Implications for Cancer Treatment - The findings indicate that the interaction between TKIs and gut microbiota could be a crucial factor in improving cancer treatment outcomes, particularly for patients who currently do not respond well to existing therapies [7][9]. - Understanding the mechanisms by which UCA enhances ICB therapy could lead to new strategies for increasing the effectiveness of cancer immunotherapy [3][11].

Core Viewpoint - Immune checkpoint blockade (ICB) therapies, represented by anti-PD-1 and anti-PD-L1 monoclonal antibodies, have significantly transformed cancer treatment, yet many patients show poor response or develop resistance to these therapies [2][6]. Group 1: Research Findings - A study published in Nature by a team from the University of Michigan reveals that the balance between STAT5 and STAT3 shapes dendritic cell (DC) function and tumor immunity, leading to the development of a STAT3-targeting PROTAC that enhances tumor sensitivity to ICB therapy [3][10]. - The research indicates that the limited number and impaired function of dendritic cells in the tumor microenvironment (TME) hinder the effectiveness of ICB therapies, emphasizing the need to understand the mechanisms behind dendritic cell phenotype formation [6][8]. Group 2: Mechanisms of Action - STAT3 is often activated in the TME, mediating immune suppression and promoting tumor growth factors, while STAT5 is activated by cytokine signals and plays a positive role in anti-tumor immune responses [7][9]. - The study found that ICB therapy reprograms the interaction between STAT3 and STAT5 pathways in dendritic cells, activating T cell immunity and enhancing the efficacy of ICB [9][10]. Group 3: Therapeutic Implications - The development of STAT3 degradation agents, such as SD-36 and SD-2301, shows promise in reprogramming dendritic cells towards an immunogenic state, effectively treating advanced tumors and those resistant to ICB therapy without toxicity [9][10]. - This research opens new avenues for cancer immunotherapy by targeting the dynamic balance between STAT3 and STAT5 in dendritic cells [10].